And Japan? [BE/BA News]

posted by ElMaestro  – Belgium?, 2019-12-04 13:43  – Posting: # 20923
Views: 564


» A: The guideline focuses on BCS-based biowaiver principles to be applied for bioequivalence purposes provided they are supported by a sound scientific rationale. The provision in the guideline that accommodates exceptions to existing regulations that do not permit BCS-based biowaivers for generic product applications, at this time, does not disqualify implementation of these harmonized technical requirements to demonstrate BCS based biowaivers for other product applications unless explicitly stated.

I tried to read that answer 10 times now and I am none the wiser. Do they mean "The guideline will deal with BCS-based biowaivers, but it is acknowledged that some countries might not accept those." ??

Le tits now.

Best regards,

Complete thread:

 Admin contact
20,255 posts in 4,263 threads, 1,398 registered users;
online 13 (0 registered, 13 guests [including 8 identified bots]).
Forum time (Europe/Vienna): 11:02 UTC

You should treat as many patients as possible with the new drugs
while they still have the power to heal.    Armand Trousseau

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz